Vir Biotechnology (VIR) Liabilities and Shareholders Equity (2018 - 2026)

Vir Biotechnology has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $1.0 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 21.57% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 billion (down 27.82% YoY) and the FY2025 annual result came in at $1.0 billion, down 28.31% from the prior year.
• Liabilities and Shareholders Equity advanced to $1.0 billion in Q1 2026 per VIR's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $2.9 billion in Q1 2022 and troughed at $1.0 billion in Q4 2025.
• A 5-year average of $1.9 billion and a median of $1.8 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 154.24% in 2022, then tumbled 32.71% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.8 billion in 2022, then sank by 31.51% to $1.9 billion in 2023, then declined by 27.11% to $1.4 billion in 2024, then fell by 28.31% to $1.0 billion in 2025, then rose by 2.27% to $1.0 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.0 billion, $1.0 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.